Stock Events

Stock Events

Longeveron 

$1.07
53
-$0.05-4.46% Thursday 20:00

Statistics

Day High
1.15
Day Low
1.04
52W High
1.83
52W Low
0.48
Volume
1,192,175
Avg. Volume
5,497,049
Mkt Cap
21.24M
P/E Ratio
3.34
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.43
-0.35
-0.26
-0.18
Expected EPS
-0.175
Actual EPS
N/A

Financials

-1,029.39%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
4.78MRevenue
-49.25MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LGVN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap2.14B
Mesoblast Limited focuses on the development of regenerative medicine, which competes directly with Longeveron's stem cell therapy products.
Biolife Solutions
BLFS
Mkt Cap1.34B
BioLife Solutions, Inc. provides bioproduction tools and services, including cell and gene therapy solutions, indirectly competing with Longeveron by supporting the broader regenerative medicine industry.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG focuses on gene editing technologies, which represent a competitive approach to Longeveron's regenerative treatments through potentially more targeted interventions.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine, Inc. is another company working on gene editing, competing with Longeveron by offering alternative solutions to medical conditions potentially treatable by regenerative medicine.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics, Inc. specializes in CRISPR/Cas9 gene editing, posing competition to Longeveron's cell therapy approach by targeting genetic diseases at their source.
Vericel
VCEL
Mkt Cap1.77B
Vericel Corporation produces autologous cell therapies for the treatment of patients with serious diseases and conditions, directly competing with Longeveron's therapeutic approach.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap6.74M
Brainstorm Cell Therapeutics Inc. works on developing innovative, autologous stem cell therapies for neurodegenerative diseases, competing in a similar niche as Longeveron.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics, Inc. is dedicated to the development of programmed cellular immunotherapies, competing with Longeveron by advancing alternative regenerative medicine and cell therapy techniques.

About

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Show more...
CEO
Dr. Joshua Michael Hare FACC, M.D.
Employees
25
Country
US
ISIN
US54303L2034

Listings

XNAS
US
LGVN
BOATS
BOATS
LGVN.BOATS

0 Comments

Share your thoughts

FAQ

What is Longeveron stock price today?▼
The current price of LGVN is $1.07 USD — it has decreased by -4.46% in the past 24 hours. Watch Longeveron stock price performance more closely on the chart.
What is Longeveron stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Longeveron stocks are traded under the ticker LGVN.
Is Longeveron stock price growing?▼
LGVN stock has risen by +16.3% compared to the previous week, the month change is a +115.77% rise, over the last year Longeveron has showed a -23.57% decrease.
What is Longeveron market cap?▼
Today Longeveron has the market capitalization of 21.24M
When is the next Longeveron earnings date?▼
Longeveron is going to release the next earnings report on May 08, 2026.
What were Longeveron earnings last quarter?▼
LGVN earnings for the last quarter are -0.23 USD per share, whereas the estimation was -0.37 USD resulting in a +37.27% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Longeveron revenue for the last year?▼
Longeveron revenue for the last year amounts to 4.78M USD.
What is Longeveron net income for the last year?▼
LGVN net income for the last year is -49.25M USD.
How many employees does Longeveron have?▼
As of April 05, 2026, the company has 25 employees.
In which sector is Longeveron located?▼
Longeveron operates in the Health Care sector.
When did Longeveron complete a stock split?▼
The last stock split for Longeveron was on March 27, 2024 with a ratio of 1:10.
Where is Longeveron headquartered?▼
Longeveron is headquartered in Miami, US.